Eli Lilly has outlined its strategy to maintain a leading position in the obesity drug market, aiming to strengthen its dominance as competition intensifies. The company’s approach centers on expanding its portfolio of GLP-1 medicines and leveraging its manufacturing capabilities to counter rivals such as Novo Nordisk, Pfizer, and Roche.
Lilly surpassed Novo Nordisk to become the primary force in the rapidly growing obesity sector. With new competitors preparing GLP-1 launches, Lilly now faces pressure to hold onto its leadership. Speaking at the J.P. Morgan Healthcare Conference, CEO Dave Ricks described this period as a shift from reliance on single products to developing broader portfolios with expanded indications. He also highlighted efforts to increase patient access through greater coverage and direct-to-consumer (DTC) sales.
BMO Capital Markets analysts expressed confidence in Lilly’s prospects, stating that they foresee “strengthening leadership in obesity and beyond.” They noted that widening patient access and the anticipated launch of a second GLP-1 molecule offer “growth and certainty” for 2026.
The company recently enhanced access by securing an agreement with the Trump administration and established DTC sales via LillyDirect, which currently serves about one million people. Ricks said improvements are planned for the platform: “improve the flow, the checkout [and] the tech behind it.”
Lilly is working to expand its range of GLP-1 drugs this year. Ricks expects FDA approval for orforglipron—an oral small molecule—in the second quarter of 2026. The timing remains uncertain due to regulatory factors; however, Ricks emphasized that approval should precede Medicare Part D access expansion: “the important thing is that the approval is ‘in front of the [Medicare] Part D access expansion, and I expect it will be.’” This would allow orforglipron availability alongside Novo’s Wegovy pill under Medicare Part D.
Analysts at BMO predict orforglipron may have an advantage over Wegovy due to fasting requirements associated with Novo’s product. However, Novo CEO Maziar Mike Doustdar raised potential restrictions related to statin use in clinical protocols for orforglipron. Ricks responded: “there’s no reason scientifically to expect anything” regarding statin use warnings on orforglipron's label.
Rival firms have invested significantly in hopes of capturing part of this market. Ricks acknowledged opportunities for newcomers focusing on specific disease niches linked to obesity: “If there’s 200 chronic diseases that are downstream affected by obesity, surely Novo and Lilly will have left one or two behind,” he said. “I think some companies will choose to niche into one of those, try to get pricing power [and] own a narrow but focused segment. That’s viable.”
Still, Ricks maintained that Lilly intends to control most of the obesity market by emphasizing both pipeline innovation and manufacturing scale—factors he believes will make it difficult for new entrants to compete effectively on price or quality.
Recent industry trends show Lilly's tirzepatide franchise reaching high sales levels much faster than previous pharmaceutical blockbusters. Both Lilly and Novo have seen significant revenue growth driven by their weight loss drugs Zepbound and Wegovy, outpacing other pharmaceutical companies.
